Recent Updates
Recently added Catalysts

KAI-7535

Phase 2

Obesity | Small Molecules | Metabolic |Kailera Therapeutics, Inc.|Trials Updated: Sep 9, 2026

KAI-7535 development status

Highest phase Phase 2
Registered trials 2 across 1 sponsor since Dec 2025

KAI-7535 target and mechanism

Molecular targetGLP-1 receptor
Target classReceptor
ModalitySmall Molecules

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials2
Total Enrollment324

FDA Designations

No designations recorded

KAI-7535 clinical trials

KAI-7535 · 2 trials · 2 indications

Phase 2 1Phase 1 1
NCT07497880Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related ComorbidityObesity
ACTIVE NOT_RECRUITING306 Analytics
PHASE2ACTIVE NOT_RECRUITING
Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity
ObesityUnlock trial analytics

Study Endpoints

Primary Endpoints

Percent Change from Baseline in Body Weight at Week 44 for Participants Without Diabetes Mellitus
Baseline, Week 44
Time to Maximum Observed Concentration (Tmax) of KAI-7535
Pre-dose and up to 60 hours post-dose
Maximum Observed Concentration (Cmax) of KAI-7535
Pre-dose and up to 60 hours post-dose
Area Under the Concentration-time Curve From 0 to Time of Last Quantifiable Concentration (AUC0-t) of KAI-7535
Pre-dose and up to 60 hours post-dose
Area Under the Concentration-time Curve From 0 to Infinity (AUC0-inf) of KAI-7535
Pre-dose and up to 60 hours post-dose

Secondary Endpoints

Change from Baseline in Body Weight at Week 44
Baseline, Week 44
Change from Baseline in Body Mass Index (BMI) at Week 44
Baseline, Week 44
Percentage of Participants at Week 44 with ≥5% and ≥10% Reduction in Body Weight
Week 44
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
KAI-7535: Dose Schedule 1EXPERIMENTALParticipants will receive KAI-7535 once daily.
KAI-7535: Dose Schedule 2EXPERIMENTALParticipants will receive KAI-7535 once daily.
KAI-7535: Dose Schedule 3EXPERIMENTALParticipants will receive KAI-7535 once daily.
KAI-7535: Dose Schedule 4EXPERIMENTALParticipants will receive KAI-7535 once daily.
PlaceboPLACEBO_COMPARATORParticipants will receive placebo matched to KAI-7535 once daily.
KAI-7535: Morning Dosing, FedEXPERIMENTALParticipants will receive KAI-7535 in the morning following a meal on dosing days.
KAI-7535: Morning Dosing, FastedEXPERIMENTALParticipants will receive KAI-7535 in the morning following an overnight fast on dosing days.
KAI-7535: Evening DosingEXPERIMENTALParticipants will receive KAI-7535 in the evening on dosing days.

Interventions

NameTypeDescription
KAI-7535DRUGOral tablets
PlaceboDRUGOral tablets
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 75 Years
SexALL
Healthy VolunteersNo
Study Sites36

Key Inclusion Criteria: * For participants without diabetes mellitus at screening and on Day 1, BMI ≥30 kilograms/square meter (kg/m\^2) or BMI ≥27 kg/m\^2 and a previous diagnosis of at least 1 of the following: * Hypertension * Dyslipidemia * Obstructive sleep apnea * Cardiovascular dise...

Countries:United StatesAustralia
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

MEDIUMOct 30, 2026NCT07497880Status: RECRUITING → ACTIVE_NOT_RECRUITING
MEDIUMOct 30, 2026NCT07497880Status: RECRUITING → ACTIVE_NOT_RECRUITING
MEDIUMOct 30, 2026NCT07497880Status: RECRUITING → ACTIVE_NOT_RECRUITING

Frequently asked questions about KAI-7535

What is KAI-7535?

KAI-7535 is an investigational oral small molecule developed by Kailera Therapeutics for the treatment of obesity. It is being studied in adults living with obesity or overweight, including those with at least one weight-related comorbidity. KAI-7535 is in Phase 2 clinical development and has not been approved by the FDA.

What does KAI-7535 target?

KAI-7535 targets the GLP-1 receptor, a receptor-class molecular target. It is a small molecule designed to act on this receptor and is being developed as an oral therapy for obesity. The GLP-1 receptor is the same target class associated with established incretin-based weight management approaches.

Who makes KAI-7535?

KAI-7535 is being developed by Kailera Therapeutics, Inc., which trades under the ticker KLRA. Kailera is the sponsor of the clinical program evaluating the drug in obesity and overweight. The company is advancing KAI-7535 as an oral small molecule candidate in the metabolic therapeutic area.

What phase is KAI-7535 in?

KAI-7535 is in Phase 2 clinical development for obesity. It is investigational and has not been approved by the FDA. The Phase 2 program includes a randomized, double-blind, placebo-controlled trial, and a completed Phase 1 study has also evaluated the drug in participants living with obesity or overweight.

What clinical trials is KAI-7535 in?

KAI-7535 has been studied in two clinical trials. NCT07497880 is an active Phase 2 trial of oral KAI-7535 in adults with obesity or overweight and at least one weight-related comorbidity, enrolling 306 participants across the United States and Australia. NCT07294898 is a completed Phase 1 study with 18 participants in the United States.

Is KAI-7535 a pill?

KAI-7535 is an oral small molecule, meaning it is designed to be taken by mouth rather than injected. Its Phase 2 trial is titled as a study of oral KAI-7535 in adults living with obesity or overweight, and a completed Phase 1 study examined the effect of a low-fat meal and evening dosing on the drug.